| Co-Investigator(Kenkyū-buntansha) |
長山 和弘 東京大学, 医学部附属病院, 助教 (00647935)
小原 收 公益財団法人かずさDNA研究所, その他部局等, 副所長 (20370926)
垣見 和宏 東京大学, 医学部附属病院, 特任教授 (80273358)
松下 博和 東京大学, 医学部附属病院, 特任講師 (80597782)
|
|---|
| Budget Amount *help |
¥16,640,000 (Direct Cost: ¥12,800,000、Indirect Cost: ¥3,840,000)
Fiscal Year 2017: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2016: ¥6,630,000 (Direct Cost: ¥5,100,000、Indirect Cost: ¥1,530,000)
Fiscal Year 2015: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
|
|---|
| Outline of Final Research Achievements |
The aim of this study was to develop personalized lung cancer vaccine targeting neoantigens. We established an algorithm to estimate individual potential neoantigens from cancer specimens using somatic mutation analysis and MHC binding predictions. Potential neoantigens were further prioritized using RNAseq data. Immunogenicity of predicted neoantigens were evaluated using healthy donor PBMC. Additionally, aiming for the personalized immunotherapy of lung cancer including neoantigen vaccines, we developed an immunogram to evaluate and visualize cancer-immunity cycle status in each patient.
|
